Figure 2.
PFS by time periods and study cohorts. (A) All patients (2000-2004 vs 2010-2014, P < .001; 2000-2004 vs 2005-2009, P < .001; 2005-2009 vs 2010-2014, P = .13). (B) ASCT-treated patients (2000-2004 vs 2010-2014, P = .23; 2000-2004 vs 2005-2009, P = .2; 2005-2009 vs 2010-2014, P = .5). (C) Standard treatment patients (2000-2004 vs 2010-2014, P < .001; 2000-2004 vs 2005-2009, P < .001; 2005-2009 vs 2010-2014, P = .53). (D) Landmark analysis at 6 months among standard treatment patients (2000-2004 vs 2010-2014, P = .02; 2000-2004 vs 2005-2009, P = .01; 2005-2009 vs 2010-2014, P = .92).

PFS by time periods and study cohorts. (A) All patients (2000-2004 vs 2010-2014, P < .001; 2000-2004 vs 2005-2009, P < .001; 2005-2009 vs 2010-2014, P = .13). (B) ASCT-treated patients (2000-2004 vs 2010-2014, P = .23; 2000-2004 vs 2005-2009, P = .2; 2005-2009 vs 2010-2014, P = .5). (C) Standard treatment patients (2000-2004 vs 2010-2014, P < .001; 2000-2004 vs 2005-2009, P < .001; 2005-2009 vs 2010-2014, P = .53). (D) Landmark analysis at 6 months among standard treatment patients (2000-2004 vs 2010-2014, P = .02; 2000-2004 vs 2005-2009, P = .01; 2005-2009 vs 2010-2014, P = .92).

Close Modal

or Create an Account

Close Modal
Close Modal